{
    "medicine_id": "3e24f6d9284abfceca4682539dc3a97163835fd7",
    "platform_id": "DB00929",
    "metadata": {
        "name": "Act Diclo miso 75 mg Tablet",
        "composition": "75 mg Misoprostol",
        "clinical_particulars": {
            "therapeutic_indications": "Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients L7616 Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers L7619 Misoprostol is used off label for the management of miscarriages prevention of post partum hemorrhage and is also used alone or in combination with mifepristone in other countries for first trimester abortions A181589 A181583 A181697",
            "contraindications": {
                "disease": "The oral LD sub 50 sub in rats is 81mg kg and in mice is 27mg kg L7613 The intraperitoneal LD sub 50 sub in rats is 40mg kg and in mice is 70mg kg L7613 Patients experiencing an overdose may present with sedation tremor convulsions dyspnea abdominal pain diarrhea fever palpitations hypotension and bradycardia A181706 L7616 L7619 Hemodialysis is not expected to be useful in the treatment of misoprostol overdose L7616 but oral activated charcoal may help reduce absorption L7619 In the event of an overdose treat symptoms with supportive therapy L7616 This may include removal of undissolved tablets from the vagina or buccal cavity intravenous fluid replacement acetaminophen diazepam haloperidol or intramuscular diclofenac depending on the symptoms that present A181706",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Misoprostol is a prostaglandin E1 analog used to reduce the risk of NSAID induced gastric ulcers by reducing secretion of gastric acid from parietal cells A181586 L7616 L7619 Misoprostol is also used to manage miscarriages and used alone or in combination with mifepristone for first trimester abortions A181589 A181583 A181598 An oral dose of misoprostol has an 8 minute onset of action and a duration of action of approximately 2 hours a sublingual dose has an 11 minute onset of action and a duration of action of approximately 3 hours a vaginal dose has a 20 minute onset of action and a duration of action of approximately 4 hours and a rectal dose has a 100 minute onset of action and a duration of action of approximately 4 hours A181607",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00429",
                        "description": "Carboprost tromethamine may increase the uterotonic activities of Misoprostol"
                    },
                    {
                        "drugbank-id": "DB00107",
                        "description": "The risk or severity of adverse effects can be increased when Misoprostol is combined with Oxytocin"
                    },
                    {
                        "drugbank-id": "DB01282",
                        "description": "The risk or severity of adverse effects can be increased when Misoprostol is combined with Carbetocin"
                    },
                    {
                        "drugbank-id": "DB01377",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB08938",
                        "description": "The risk or severity of adverse effects can be increased when Magaldrate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB09104",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB09281",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium trisilicate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB09481",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB13249",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium silicate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB13322",
                        "description": "The risk or severity of adverse effects can be increased when Hydrotalcite is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB13486",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium peroxide is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB00653",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB01397",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB09407",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium chloride is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB11110",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium citrate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB13359",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB13749",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB13786",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium orotate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB14513",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB14514",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium levulinate is combined with Misoprostol"
                    },
                    {
                        "drugbank-id": "DB14515",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium lactate is combined with Misoprostol"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}